Skip to main content

Table 1 Baseline characteristics of the subjects enrolled in the present study

From: Increased serum C1q-binding adiponectin complex to total-adiponectin ratio in men with multi-vessel coronary disease

  Non-CAD group Single-vessel group p value (Non-CAD group versus Single-vessel group) Multi-vessels group p value (Non-CAD group versus Multi-vessels group) p value (Single-vessel group versus Multi-vessels group)
Number 15 22   16   
Age, years 65 ± 2 65 ± 2 0.910 66 ± 2 0.889 0.817
Body mass index, kg/m2 25.0 ± 0.9 23.8 ± 0.7 0.666 25.6 ± 1.0 0.359 0.135
Visceral fat area, cm2 111 ± 14 121 ± 14 0.205 123 ± 14 0.255 0.898
Subcutaneous fat area, cm2 137 ± 18 138 ± 12 0.341 141 ± 11 0.394 0.918
Smoking (none-/ex-/current-smoker), n 8/5/2 9/5/8 0.566 3/4/9 0.149 0.230
Diabetes mellitus, n 9 11 0.644 9 0.879 0.793
Sulfonyl ureas/glinides/biguanides/alpha glucosidase inhibitors/Insulin, n 5/0/1/1/2 7/5/6/1/2   4/0/1/4/2   
Hypertension, n 13 16 0.436 11 0.392 0.886
Calcium channel antagonists/angiotensin receptor blockers/β-blockers/diuretics, n 8/2/2/0 13/12/4/2   6/8/6/2   
Dyslipidemia, n 7 14 0.430 10 0.525 0.965
Statins/fibrates/ezetimibe/cholestimide, n 5/1/0/0 10/0/1/1   9/1/0/0   
Anti-platelet drugs (aspirin/ticlopidine/clopidogrel), n 4/0/2 22/0/22   16/6/10   
Family history of CAD, n 2 2 0.753 5 0.392 0.116
Systolic blood pressure, mmHg 134 ± 4 137 ± 4 0.808 139 ± 5 0.981 0.802
Diastolic blood pressure, mmHg 78 ± 2 74 ± 2 0.135 77 ± 3 0.586 0.407
Hemoglobin A1c (NGSP),% 6.9 ± 0.5 6.4 ± 0.2 0.255 6.6 ± 0.4 0.661 0.519
LDL-C, mg/dL 123 ± 6 110 ± 7 0.193 113 ± 9 0.789 0.132
Triglyceride, mg/dL 124 ± 16 152 ± 19 0.290 125 ± 12 0.969 0.273
HDL-C, mg/dL 61 ± 4 57 ± 4 0.352 48 ± 3 0.005* 0.139
Creatinine, mg/dL 0.82 ± 0.04 0.87 ± 0.06 0.880 0.82 ± 0.02 0.475 0.510
Target lesions (LMCA/LAD/LCX/RCA), n - 0/20/1/1   1/40/13/2   
ACC/AHA (Type A/B/C) - 6/12/4   5/7/4   
Procedures (PCI/CABG), n - 22/0   15/1   
  1. Data are mean ± SEM, or number of subjects analyzed. Differences among groups were compared by one- or two-way analysis of variance (ANOVA) with Fisher's protected least significant difference test for multiple-group analysis. Differences in frequencies were examined by the χ2 test. CAD, coronary artery disease; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; LMCA, left main coronary artery; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.